There is a growing prevalence of pancreatic cancer, accompanied by accelerated disease progression and diminished survival rates. Radical resection with clear margins remains the sole viable option for achieving a long-term cure in patients. In cases of advanced, unresectable, and metastatic disease, chemotherapy based on leucovorin, 5-fluorouracil, irinotecan, oxaliplatin, gemcitabine, or nab-paclitaxel represents the cornerstone of the treatment. Considering the limited treatment options available following initial therapy, the strategy of repurposing commonly prescribed drugs such as antihypertensives into anti-cancer therapies in palliative treatment represents a promising avenue for enhancing survival in patients with pancreatic ductal adenocarcinoma. The repurposing of existing drugs is typically a more cost-effective and expedient strategy than the development of new ones. The potential for antihypertensive drugs to be employed as adjunctive therapies could facilitate a more comprehensive treatment approach by targeting multiple pathways involved in cancer progression and acquired resistance to treatment. Antihypertensive medications, particularly those belonging to the pharmacological classes of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and calcium channel blockers, are commonly prescribed and have well-established safety profiles, particularly among patients with pancreatic cancer who are affected by multiple comorbidities. Therefore, we emphasize the preclinical and clinical evidence supporting the use of antihypertensive agents in the treatment of pancreatic cancer, emphasizing their beneficial chemosensitizing effects.
胰腺癌的发病率日益上升，疾病进展加速，生存率不断降低。根治性切除并确保切缘阴性仍是患者获得长期治愈的唯一可行选择。对于晚期、不可切除及转移性病例，以亚叶酸、5-氟尿嘧啶、伊立替康、奥沙利铂、吉西他滨或白蛋白结合型紫杉醇为基础的化疗是治疗的基石。鉴于初始治疗后可选治疗方案有限，将常用处方药（如降压药）重新定位为姑息治疗中的抗癌疗法，成为提高胰腺导管腺癌患者生存率的新途径。与开发新药相比，现有药物的再利用通常是一种更具成本效益且更快捷的策略。降压药作为辅助疗法的潜力，可通过靶向癌症进展和获得性治疗耐药所涉及的多种通路，促进更全面的治疗方案。降压药物，特别是血管紧张素转换酶抑制剂、血管紧张素II受体阻滞剂和钙通道阻滞剂等药理类别的药物，应用广泛且安全性明确，尤其适用于患有多种合并症的胰腺癌患者。因此，我们重点阐述了支持降压药用于胰腺癌治疗的临床前和临床证据，强调其有益的化疗增敏作用。
肿瘤(癌症)患者之家